Comparison of the hypoxia PET tracer 18F-EF5 to immunohistochemical marker EF5 in 3 different human tumor xenograft models

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1192-1197

  Chitneni, Satish K ^a   Bida, Gerald T ^a   Zalutsky, Michael R ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EF5; Hypoxia; PET; Tumor

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL) ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL) ACETAMIDE F 18; HOE 33342; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; 2-(2-NITRO-1H-IMIDAZOL-1-YL)-N-(2,2,3,3,3-PENTAFLUOROPROPYL)ACETAMIDE; BENZIMIDAZOLE DERIVATIVE; ETANIDAZOLE; FLUORINATED HYDROCARBON; FLUORINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CHEMICAL BINDING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; RAT; TUMOR SCINTISCANNING; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL HYPOXIA; CELL TRANSFORMATION; COMPARATIVE STUDY; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ETANIDAZOLE; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 84904110347     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.137448     Document Type: Article

References (27)

1. 2 tension measurements. Cancer Res. 1991;51:3316-3322.
2. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289. (Pubitemid 27318643)
3. Milosevic M, Warde P, Menard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res. 2012;18:2108-2114.
4. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207-214.
5. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441-1454.
6. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425-437. (Pubitemid 351744964)
7. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
8. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 2001;24:467-472. (Pubitemid 32959104)
9. 2 histography. Antioxid Redox Signal. 2007;9:1221-1235. (Pubitemid 47080831)
10. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med. 2011;52:165-168.
11. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49:1944-1951.
12. 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging. 2010;37:2048-2059.
13. 18F-EF5 in oncologic patients. Cancer Biother Radiopharm. 2012;27:412-419.
14. 18F-FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157-164.
15. 18F- fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med. 2011;52:437-444.
16. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004;64:1886-1892. (Pubitemid 38428715)
17. Evans SM, Fraker D, Hahn SM, et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2006;64:922-927. (Pubitemid 43183594)
18. Evans SM, Du KL, Chalian AA, et al. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys. 2007;69:1024-1031. (Pubitemid 47625842)
19. 18F-EF5). Nucl Med Biol. 2012;39:1012-1018.
20. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. J Nucl Med. 2013;54:1339-1346.
21. 18F-EF5. Mol Imaging Biol. 2012;14:205-212.
22. 124I-labeled iodoazomycin galactopyranoside PET. Radiology. 2008;248:561-570.
23. 64Cu(II)-diacetylbis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989-998.
24. 18F-EF5. Eur J Nucl Med Mol Imaging. 2003;30:259-266. (Pubitemid 36686845)
25. 18F-EF5 uptake. Int J Radiat Biol. 2009;85:1137-1147.
26. 18F-EF5 and positron emission tomography. BJU Int. 2007;99:1154-1160.
27. Koch CJ, Hahn SM, Rockwell K, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol. 2001;48:177-187. (Pubitemid 32758891)